Navigation Links
For super-obese patients, duodenal switch beats gastric bypass

loss. DS patients lost more total weight and a larger percentage of excess body weight and consequently had a bigger decrease in BMI. When they were weighed one year after surgery, DS patients had lost an average of 149 pounds compared to 121 pounds for RYGB patients. After three years, DS patients had lost 173 pounds, but average weight loss for RYGB patients had decreased to 118 pounds.

"Every one of these patients had significant weight loss," Prachand said, "but the duodenal-switch patients had greater weight loss and seemed to keep the weight off longer."

"There has been a perception amongst bariatric surgeons that the duodenal switch might provide better weight loss than gastric bypass in super-obese individuals," said Prachand. Several studies have demonstrated higher rates of weight-loss failure and weight regain following gastric bypass in these patients.

But surgeons have been hesitant to adopt the duodenal switch for several reasons, he said: "greater technical complexity of the operation, particularly when performed laparoscopically; greater potential for nutritional deficiencies; and need for life-long medical follow-up."

"Given these concerns," he said, "it would be difficult to recommend duodenal switch without demonstrating a significant advantage over the gastric bypass, which is generally a very effective operation in severely obese patients. Our study demonstrates an advantage with regards to weight loss."

"We still need longer-term data on these patients," he added. "We are currently comparing nutritional outcomes and improvement in obesity-related medical problems, including type 2 diabetes, high blood pressure, elevated cholesterol levels, acid reflux, and obstructive sleep apnea in these patients. We don't know yet how much weight loss we need to get those health benefits, but losing more of the excess weight certainly seems to be better."
'"/>

Source:University of Chicago Medical Center


Page: 1 2 3

Related biology news :

1. In SAD patients, autumn antidepressants can prevent winter depression
2. Scientists ID molecular switch in liver that triggers harmful effects of saturated and trans fats
3. Bad aftertaste? New sensory on/off switch may cure bane of artificial sweetener search
4. Beetle-inspired switch uses water for bonding
5. Single gene is genetic switch for fly sexual behavior
6. UT Southwestern researchers discover master switch in cell death
7. A dimmer switch for genes
8. Scientists discover the molecular switch for nerve cells insulating jelly rolls
9. Switching to new anti-bacterial targets: Riboswitches
10. Hot-spring bacteria flip a metabolic switch
11. Animal models show that anabolic steroids flip the adolescent brains switch for aggression
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: For super obese patients duodenal switch beats gastric bypass

(Date:7/9/2015)... 9, 2015  Synaptics Inc. (NASDAQ: SYNA ), a ... it will report financial results for the fourth quarter ... after the close of market. The company will host ... 2:00 p.m. PT (5:00 p.m. ET), during which management ... on the live call, analysts and investors should dial ...
(Date:7/8/2015)... FRANKLIN LAKES , N.J. and NEW YORK ... and Company) and Guidepoint today announced ... selected start-up healthcare companies with free access to Guidepoint,s ... mentoring several start-ups that are developing cutting-edge technologies to ... of a dedicated Guidepoint research manager, each start-up entrepreneur ...
(Date:7/7/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company") ... announces a revised version of one of its first 30 second ... CNBC in New York , Chicago ... San Francisco metro areas.    , , ... replace all the cards in your wallet and keep your identity ...
Breaking Biology News(10 mins):Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 3Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 3
... cells derived from muscle have a greater ability to regenerate ... at Children’s Hospital of Pittsburgh of UPMC. , The study, ... the Journal of Cell Biology, is the first ever to ... based on sex. , This finding could have a ...
... was published in an advance online edition of the Proceedings ... April 9, 2007. , The study provides new evidence that ... is activated by the protein SGT1, which also activates Resistance ... pathogens. The study also confirms structural similarities between the Nod1 ...
... absorb carbon dioxide as they grow—can help to remove ... suggests that, as a way to fight global warming, ... these trees are planted. In particular, tropical forests are ... healthy temperature. , The researchers, including Ken Caldeira of ...
Cached Biology News:The sturdier sex? -- Study by Pittsburgh scientists finds female stem cells work better 2Scripps research study shows humans and plants share common regulatory pathway 2Scripps research study shows humans and plants share common regulatory pathway 3Tropical forests -- Earth's air conditioner 2
(Date:7/30/2015)... ... , ... The 2015 Market Research Report on the Global Propanol Industry ... Propanol market with a focus on the Chinese situation. Major companies included in the ... Chemical, Sanofi, Royal Dutch Shell, LG Chem and Zhejiang Xinhua Chemical. , The report ...
(Date:7/30/2015)... ... July 30, 2015 , ... Leading regenerative ... study of its canine osteoarthritis stem cell product, currently under development for FDA ... and will be marketed in the US by Aratana. This product, termed AT-016, ...
(Date:7/30/2015)... July 30, 2015   Senomyx , Inc. (NASDAQ: ... science technologies to discover, develop, and commercialize novel flavor ... today reported financial results for the second quarter 2015. ... 2015, we remain on track to achieve our commercial ... Executive Officer of the Company. "Since our last quarterly ...
(Date:7/30/2015)... COPENHAGEN, Denmark , July 30, 2015 /PRNewswire/ ... a biotechnology company that applies its innovative TransCon ... announced positive top-line results from a six-month Phase ... of once-weekly TransCon Growth Hormone in 53 treatment-naïve, ... "We are extremely pleased with the ...
Breaking Biology Technology:Global Propanol Market Technical Data and Manufacturing Analysis 2020 2Global Propanol Market Technical Data and Manufacturing Analysis 2020 3VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 3SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 2SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 3SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 4SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 5SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 6SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 7SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 8SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 9Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7
... will use health information technology to,accelerate the ... across,the U.S., WASHINGTON, Nov. 29 ... the formation of an innovative,research program designed ... eHI,Connecting Communities for Drug Safety Collaboration is ...
... Global Ventures today,announced that it will soon be launching ... Fund will invest in private Israeli related,technology companies that ... and,have a proven business model. First closing is scheduled ... Jerusalem Global in 1994, notes that,"Unlike the early stage ...
... controlling the magnetic properties of a commonly used blue ... published recently in Advanced Materials. , Scientists have demonstrated ... known as Metal Phthalocyanine, or MPc, with the use ... in its infancy, researchers claim that the ability to ...
Cached Biology Technology:eHealth Initiative Foundation Launches Collaborative Research Effort to Improve Drug Safety 2eHealth Initiative Foundation Launches Collaborative Research Effort to Improve Drug Safety 3eHealth Initiative Foundation Launches Collaborative Research Effort to Improve Drug Safety 4eHealth Initiative Foundation Launches Collaborative Research Effort to Improve Drug Safety 5eHealth Initiative Foundation Launches Collaborative Research Effort to Improve Drug Safety 6Jerusalem Global Ventures Announces $200 Million Growth Equity Fund 2Blue dye could hold the key to super processing power 2Blue dye could hold the key to super processing power 3
Dnase and Rnase free...
TLN2 Antibody...
Mouse monoclonal [0.N.305] to G protein alpha - BSA and Azide free ( Abpromise for all tested applications). Antigen: Partially purified G protein alpha from rat brain. Entrez GeneID: 2778 ...
Rabbit polyclonal to VEGF Receptor 2 (phospho Y1214) ( Abpromise for all tested applications). entrezGeneID: 3791 SwissProtID: P35968...
Biology Products: